Darolutamide for non-metastatic castration-resistant prostate cancer: Efficacy, safety, and clinical perspectives of use
Journal
Journal of the Formosan Medical Association = Taiwan yi zhi
Journal Volume
122
Journal Issue
4
Date Issued
2023-04
Author(s)
Yang, Cheng-Kuang
Cha, Tai-Lung
Chang, Yen-Hwa
Huang, Shu-Pin
Lin, Jen-Tai
Wang, Shian-Shiang
Pang, See-Tong
Abstract
Darolutamide, a second-generation androgen receptor inhibitor (SGARI), has been shown to increase metastasis-free survival and overall survival among men with non-metastatic castration-resistant prostate cancer (nmCRPC). Its unique chemical structure potentially provides efficacy and safety advantages over the SGARIs apalutamide and enzalutamide, which are also indicated for nmCRPC. Despite a lack of direct comparisons, the SGARIs appear to have similar efficacy, safety, and quality of life (QoL) results. Indirect evidence suggests that darolutamide is preferred for its good adverse event profile, an attribute valued by physicians, patients, and their caregivers for maintaining QoL. Darolutamide and others in its class are costly; access may be a challenge for many patients and may lead to modifications to guideline-recommended regimens.
Subjects
Apalutamide; Castration-resistant prostate cancer; Darolutamide; Enzalutamide; Second-generation androgen receptor inhibitor
SDGs
Type
review